WWP1 and prostate cancer: The copy number gain of WWP1 has been reported in 51% of breast cancer cell lines; 41% of primary breast tumors; 35% of oral cancer samples; 44% of prostate cancer cell lines and xenografts; and 31% of clinical prostate cancer samples [9].